story of the week
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
J. Clin. Oncol 2021 Apr 12;[EPub Ahead of Print], AS Alva, PK Mangat, E Garrett-Mayer, S Halabi, D Hansra, CJ Calfa, MF Khalil, ER Ahn, TL Cannon, P Crilley, JG Fisher, DS Haslem, S Shrestha, KR Antonelli, NL Butler, SL Warren, AL Rygiel, S Ranasinghe, SS Bruinooge, RL SchilskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.